Special Issue "Viral and Host Factors Driving the Emergence and the Evolution of the SARS-CoV-2 and Other Coronaviruses"
Deadline for manuscript submissions: 30 April 2022.
2. AIOVA sas, University of Grenoble, 570 rue de la Chimie, 38300 Saint Martin d’Hèyres, France
Interests: infectiology; molecular and cellular biology; virology; emerging and re-emerging viral infections; vaccines; SARS-CoV; retro- and lentiviruses; influenza; gene therapy; gene transfer vectors
Eighteen months ago, humanity was facing the emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic. This emergence, from an animal reservoir, is the third in just two decades after the SARS-CoV-1 in 2002 and the MERS in 2012. Thus, new SARS pandemics are likely to occur in the future.
SARS viruses undergo continuous genetic changes. Thousands of SARS-CoV-2 variants have been detected by laboratory screening. Four of them (from United Kingdom, South Africa, Brazil and India) that may have enhanced transmission and pathogenicity are emerging and are of great concern. Regarding the vaccines authorized to date for an emergency use, there is also concern about the reduction in vaccine-induced immune protection to emerging variants.
The complex questions to explore are : (i) what makes a SARS virus transmissible from one species to another, and (ii) which factors drive mutation, evolution and emergence of SARS. Understanding these questions will provide us with better tools to controlling COVID.
The aim of this special issue is to provide data on the viral, cellular and host factors involved in the emergence and evolution of the SARS viruses. Several factors are in question such as the viral dynamic, the RNA nature of the virus - ability to mutate, the role of co-infections and recombinations -, host and cellular restriction factors as well as host immunity and immune escape.
Papers focusing on animal coronaviruses that may be relevant to SARS-CoV-2 are welcome.
Dr. Corinne Ronfort
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- SARS-CoV-2, SARS, MERS
- biology of SARS CoV-2 and other coronaviruses
- viral evolution, variants
- host factors
- innate and adaptive immunity
- crossing of the species barrier